S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
First-Time Investor? Here Are 9 Mistakes You Want To Avoid
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Ford Stock Going Forward After Big Earnings Flop
Are Penny Stocks Worth it? Should You Invest in Penny Stocks?
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Closing prices for crude oil, gold and other commodities
AI Software Maker EPAM Boasts Biggest Tech-Sector Rally
“Future Fuel” will unleash $11 trillion wave of wealth (Ad)
Indian tycoon Adani hit by more losses, calls for probe
Ford, Starbucks fall; Clorox, Gilead Sciences rise
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
First-Time Investor? Here Are 9 Mistakes You Want To Avoid
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Ford Stock Going Forward After Big Earnings Flop
Are Penny Stocks Worth it? Should You Invest in Penny Stocks?
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Closing prices for crude oil, gold and other commodities
AI Software Maker EPAM Boasts Biggest Tech-Sector Rally
“Future Fuel” will unleash $11 trillion wave of wealth (Ad)
Indian tycoon Adani hit by more losses, calls for probe
Ford, Starbucks fall; Clorox, Gilead Sciences rise
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
First-Time Investor? Here Are 9 Mistakes You Want To Avoid
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Ford Stock Going Forward After Big Earnings Flop
Are Penny Stocks Worth it? Should You Invest in Penny Stocks?
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Closing prices for crude oil, gold and other commodities
AI Software Maker EPAM Boasts Biggest Tech-Sector Rally
“Future Fuel” will unleash $11 trillion wave of wealth (Ad)
Indian tycoon Adani hit by more losses, calls for probe
Ford, Starbucks fall; Clorox, Gilead Sciences rise
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
First-Time Investor? Here Are 9 Mistakes You Want To Avoid
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Ford Stock Going Forward After Big Earnings Flop
Are Penny Stocks Worth it? Should You Invest in Penny Stocks?
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Closing prices for crude oil, gold and other commodities
AI Software Maker EPAM Boasts Biggest Tech-Sector Rally
“Future Fuel” will unleash $11 trillion wave of wealth (Ad)
Indian tycoon Adani hit by more losses, calls for probe
Ford, Starbucks fall; Clorox, Gilead Sciences rise
NASDAQ:ACOR

Acorda Therapeutics - ACOR Stock Forecast, Price & News

$0.98
+0.01 (+1.03%)
(As of 02/3/2023 12:00 AM ET)
Add
Compare
Today's Range
$0.97
$1.04
50-Day Range
$0.52
$1.00
52-Week Range
$0.26
$2.29
Volume
128,148 shs
Average Volume
295,533 shs
Market Capitalization
$23.82 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
ACOR stock logo

About Acorda Therapeutics (NASDAQ:ACOR) Stock

Acorda Therapeutics, Inc. engages in the development of therapies that restore function and improve the lives of people with neurological disorders. Its products include Inbrija (levodopa inhalation powder), Ampyra (dalfampridine), Fampyra (fampridine) and Selincro (nalmefene). The firm's also offers Research and Development Programs like ARCUS for acute migraine, Cimaglermin alfa and rHIgM22. The company was founded by Ronald Cohen in 1995 and is headquartered in Ardsley, NY.

Receive ACOR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Acorda Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ACOR Stock News Headlines

A gold storm is coming…
“We are in the early stages of a mania – the calm before the storm.”...
StockNews.com Upgrades Acorda Therapeutics (NASDAQ:ACOR) to "Buy"
A gold storm is coming…
“We are in the early stages of a mania – the calm before the storm.”...
Acorda Edges up on Making Interest Payment
See More Headlines
Receive ACOR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Acorda Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ACOR Company Calendar

Last Earnings
11/09/2021
Today
2/04/2023
Next Earnings (Estimated)
3/08/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:ACOR
CUSIP
00484M10
Employees
118
Year Founded
1995

Profitability

Net Income
$-103,950,000.00
Pretax Margin
-61.03%

Debt

Sales & Book Value

Annual Sales
$129.07 million
Book Value
$13.49 per share

Miscellaneous

Free Float
23,768,000
Market Cap
$23.82 million
Optionable
Optionable
Beta
1.43

Social Links


Key Executives

  • Ronald Cohen
    President, Chief Executive Officer & Director
  • Michael Gesser
    Chief Financial Officer & Treasurer
  • Kerry Clem
    Chief Commercial Officer
  • Burkhard Blank
    Head-Drug Safety
  • Sofia Ali
    Senior VP-Operations & Strategic Planning













ACOR Stock - Frequently Asked Questions

How have ACOR shares performed in 2023?

Acorda Therapeutics' stock was trading at $0.7667 at the beginning of the year. Since then, ACOR shares have increased by 28.0% and is now trading at $0.9810.
View the best growth stocks for 2023 here
.

When is Acorda Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 8th 2023.
View our ACOR earnings forecast
.

How were Acorda Therapeutics' earnings last quarter?

Acorda Therapeutics, Inc. (NASDAQ:ACOR) released its quarterly earnings results on Tuesday, November, 9th. The biopharmaceutical company reported ($1.43) EPS for the quarter, beating analysts' consensus estimates of ($1.56) by $0.13. The biopharmaceutical company earned $31.46 million during the quarter, compared to the consensus estimate of $30.57 million. Acorda Therapeutics had a negative net margin of 85.97% and a negative trailing twelve-month return on equity of 96.44%.

When did Acorda Therapeutics' stock split?

Acorda Therapeutics's stock reverse split on Monday, January 4th 2021. The 1-6 reverse split was announced on Thursday, December 31st 2020. The number of shares owned by shareholders was adjusted after the market closes on Thursday, December 31st 2020. An investor that had 100 shares of stock prior to the reverse split would have 17 shares after the split.

What guidance has Acorda Therapeutics issued on next quarter's earnings?

Acorda Therapeutics issued an update on its FY 2022 earnings guidance on Thursday, December, 22nd. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $116.00 million-$119.70 million, compared to the consensus revenue estimate of $120.51 million.

What is Ron Cohen's approval rating as Acorda Therapeutics' CEO?

39 employees have rated Acorda Therapeutics Chief Executive Officer Ron Cohen on Glassdoor.com. Ron Cohen has an approval rating of 55% among the company's employees. This puts Ron Cohen in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Acorda Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Acorda Therapeutics investors own include Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), ADMA Biologics (ADMA), InterDigital (IDCC), Nektar Therapeutics (NKTR), Rigel Pharmaceuticals (RIGL), Novan (NOVN), SCYNEXIS (SCYX), Acasti Pharma (ACST) and Applied Materials (AMAT).

What is Acorda Therapeutics' stock symbol?

Acorda Therapeutics trades on the NASDAQ under the ticker symbol "ACOR."

Who are Acorda Therapeutics' major shareholders?

Acorda Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Simplex Trading LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%).
View institutional ownership trends
.

How do I buy shares of Acorda Therapeutics?

Shares of ACOR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Acorda Therapeutics' stock price today?

One share of ACOR stock can currently be purchased for approximately $0.98.

How much money does Acorda Therapeutics make?

Acorda Therapeutics (NASDAQ:ACOR) has a market capitalization of $23.82 million and generates $129.07 million in revenue each year. The biopharmaceutical company earns $-103,950,000.00 in net income (profit) each year or ($7.01) on an earnings per share basis.

How many employees does Acorda Therapeutics have?

The company employs 118 workers across the globe.

How can I contact Acorda Therapeutics?

Acorda Therapeutics' mailing address is 420 SAW MILL RIVER ROAD, ARDSLEY NY, 10502. The official website for the company is www.acorda.com. The biopharmaceutical company can be reached via phone at (914) 347-4300 or via fax at 914-347-4560.

This page (NASDAQ:ACOR) was last updated on 2/4/2023 by MarketBeat.com Staff